Annexin Pharmaceuticals AB Logo

Annexin Pharmaceuticals AB

Clinical-stage biotech developing a cell-protecting biologic for RVO and oncology.

ANNX | ST

Overview

Corporate Details

ISIN(s):
SE0009664154
LEI:
5493000JP703HGPJEX27
Country:
Sweden
Address:
KAMMAKARGATAN 48, 111 60 Stockholm

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on developing ANXV, a recombinant human protein, Annexin A5. This first-in-class biologic acts as a cell protector and immune modulator by targeting and binding to phosphatidylserine (PS), a lipid exposed on the surface of stressed, damaged, or cancerous cells. This mechanism forms a protective shield, counteracting cellular stress, reducing inflammation, and helping damaged cells recover. The company's lead program is evaluating ANXV in a Phase 2 clinical study for the treatment of Retinal Vein Occlusion (RVO), a common cause of vision impairment. ANXV is also being investigated for its potential in oncology, where it may enable the immune system to attack cancer cells. The drug candidate's fundamental mode of action provides broad therapeutic potential across various diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Annexin Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.